Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography–tandem mass spectrometry-Reference-Cited by-同舟云学术

Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography–tandem mass spectrometry

Published:2022-08 Issue:11 Volume:36 Page:
ISSN:0269-3879
Container-title:Biomedical Chromatography
language:en
Short-container-title:Biomedical Chromatography

Author:

Susam M. Merve¹²,Wang Jing³,Schinkel Alfred H.³,Beijnen Jos H.¹²³,Sparidans Rolf W.⁴^ORCID

Affiliation:

1. Department of Pharmacy and Pharmacology The Netherlands Cancer Institute, CX Amsterdam The Netherlands

2. Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology Utrecht University, CG Utrecht The Netherlands

3. Division of Pharmacology The Netherlands Cancer Institute, CX Amsterdam The Netherlands

4. Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacology Utrecht University, CG Utrecht the Netherlands

Publisher

Wiley

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,General Medicine,Biochemistry,Analytical Chemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bmc.5457

Reference12 articles.

1. Structure elucidation of aplidine metabolites formedin vitro by human liver microsomes using triple quadrupole mass spectrometry

2. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research

3. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors

4. European Medicines Agency. (2011).2** Committee for Medicinal Products for Human Use (CHMP) Guideline on bioanalytical method validation.https://www.ema.europa.eu/contact

5. FDA &CDER. (2018).Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Contains Nonbinding Recommendations.http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htmand/orhttp://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioanalysis of anticancer agents: Evaluating LC-MS/MS procedures with greenness metrics;TrAC Trends in Analytical Chemistry;2023-12

2. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure;Pharmaceuticals;2022-09-08